Immatics Announces Full Year 2022 Financial Results and Corporate Update
In October 2022, Immatics provided an interim update on the ongoing IMA203 TCR-T monotherapy trial covering data from 27 patients in the completed Phase 1a dose escalation and the first 5 patients in the Phase 1b dose expansion trial.
- In October 2022, Immatics provided an interim update on the ongoing IMA203 TCR-T monotherapy trial covering data from 27 patients in the completed Phase 1a dose escalation and the first 5 patients in the Phase 1b dose expansion trial.
- This allows Immatics to shorten the turnaround time and to provide the cell therapy product candidate to patients faster.
- In October 2022, GSK provided Immatics with notice of its decision to terminate their collaboration.
- Immatics successfully completed an underwritten public offering in October 2022, raising approximately $110 million before deducting underwriting discount and offering expenses.